COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,248 Articles (22,733 medRxiv, 8,515 bioRxiv)

Most recent first Previous |  Page 2213: Articles 22121-22130  | Next

An optimal control policy for COVID-19 pandemic until a vaccine deployment
Sayarshad, H. R.
10.1101/2020.09.26.20202325 — Posted: 2020-09-28
Evolution of COVID-19 cases in selected low- and middle-income countries: past the herd immunity peak?
Lexmond, A. S., Nouwen, C. J., Callan, J. P.
10.1101/2020.09.26.20201814 — Posted: 2020-09-28 Discussion: Onsite
Improved Sensitivity, Safety, and Rapidity of COVID-19 Tests by Replacing Viral Storage Solution with Lysis Buffer
Erster, O., Shkedi, O., Benedek, G., Zilber, E., Varkovitzky, I., Shirazi, R., Oriya Shorka, D., Cohen, Y., Bar, T., Tepperberg Oikawa, M., Venkert, D., Linial, M., Oiknine-Djian, E., Mandelboim, M., Livneh, Z., Shenhav-Saltzman, G., Mendelson, E., Wolf, D., Szwarcwort-Cohen, M., Mor, O., Lewis, Y., Zeevi, D.
10.1101/2020.09.25.20201921 — Posted: 2020-09-28
The quantitative landscape of the neutralizing antibody response to SARS-CoV-2
Padmanabhan, P., Desikan, R., Dixit, N. M.
10.1101/2020.09.25.20201996 — Posted: 2020-09-28
A Multi-center Study of COVID-19 with Multivariate Prognostic Analysis
Zeng, W., Feng, X., Huang, J., Du, C., Qu, D., Zhang, X., Zhang, j.
10.1101/2020.09.26.20202234 — Posted: 2020-09-28
Wide variabilities identified among spike proteins of SARS Cov2 globally-dominant variant identified
Pal, A., Pal, A.
10.1101/2020.09.26.314385 — Posted: 2020-09-27
Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection
Rosenke, K., Meade-White, K., Letko, M. C., Clancy, C., Hansens, F., Liu, Y., Okumura, A., Tang-Huau, T.-L., Li, R., Saturday, G., Feldmann, F., Scott, D., Wang, Z., Munster, V., Jarvis, M., Feldmann, H.
10.1101/2020.09.25.314070 — Posted: 2020-09-27
Modeling COVID-19 as a National Dynamics with a SARS-CoV-2 Prevalent Variant: Brazil - A Study Case
Celaschi, S.
10.1101/2020.09.25.20201558 — Posted: 2020-09-27
Self-sampling of capillary blood for serological testing of SARS-CoV-2 by COVID-19 IgG ELISA
Brown, L., Byrne, R. L., Fraser, A., Owen, S. I., Cubas Atienzar, A. I., Williams, C., Kay, G. A., Cuevas, L. E., Fitchett, J. R. A., Fletcher, T., Garrod, G., Kontogianni, K., Krishna, S., Menzies, S., Planche, T., Sainter, C., Staines, H. M., Turtle, L., Adams, E. R.
10.1101/2020.09.25.20183459 — Posted: 2020-09-27
Onset, duration, and persistence of taste and smell changes and other COVID-19 symptoms: longitudinal study in Israeli patients
Klein, H., Asseo, K., Karni, N., Benjamini, Y., Nir-Paz, R., Muszkat, M., Israel, S., Niv, M. Y.
10.1101/2020.09.25.20201343 — Posted: 2020-09-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).